Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Beryl Drugs Ltd (524606)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524606 NSE: Pharmaceuticals & Drugs | Small Cap | Beryl Drugs Share Price
₹23.23 -0.73 (-3.05%)
As on 25-Sep'26 16:59
Beryl Drugs Ltd (524606)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524606 NSE: Pharmaceuticals & Drugs | Small Cap | Beryl Drugs Share Price
₹23.23 -0.73 (-3.05%)
As on 25-Sep'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹12 Cr.
Current Price
₹23.2
52-Week Low / High
₹16 / 28
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
54.9
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-20.88%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
27.82%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
-
Equity
₹5.1 Cr.
Face Value
₹10
All Time Low / High
₹0.60 / 53.00
Check Before You Invest
M-Cap below 100cr DeciZen not available
Is Beryl Drugs Ltd a good quality company?
Beryl Drugs Ltd is a quality company, based on a multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Beryl Drugs Ltd performance compare with that of its Peers?
Revenue growth of Beryl Drugs Ltd vs industry peers?
Beryl Drugs Ltd revenue CAGR is %, compared to the industry median CAGR of 0%, indicating stable growth and maintaining its market share.
Promoter shareholding and pledge status of Beryl Drugs Ltd?
Promoters hold 27.82% of the Beryl Drugs Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Beryl Drugs Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 3.2% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Beryl Drugs Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 5.6% | 4.5% | 16.9% | 10% | 4.1% | 6.3% | -3.8% | 11.5% | 11.1% | 10.2% | - |
| Value Creation Index ⓘ | -0.6 | -0.7 | 0.2 | -0.3 | -0.7 | -0.6 | -1.3 | -0.2 | -0.2 | -0.3 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 13.1 | 11 | 15.1 | 13 | 12.8 | 14.1 | 14.6 | 26.9 | 26.7 | 21.2 | 21 |
| Sales YoY Gr. | - | -16.2% | 37.8% | -14.4% | -1.1% | 9.9% | 3.6% | 84% | -0.5% | -20.9% | - |
| Adj EPS ⓘ | 0.2 | 0.2 | 1.3 | 1.2 | 0.1 | -0.2 | -1.3 | 1.5 | 1.5 | 1.1 | 1.2 |
| YoY Gr. | - | 16.7% | 528.6% | -10.6% | -92.4% | -266.7% | NA | NA | -0.7% | -24% | - |
| BVPS (₹) ⓘ | 13.1 | 13.4 | 13.1 | 14.8 | 15 | 15.6 | 14.3 | 15.9 | 17.6 | 18.7 | 19.9 |
| Adj Net Profit ⓘ | 0.1 | 0.1 | 0.7 | 0.6 | 0.1 | -0.1 | -0.7 | 0.8 | 0.8 | 0.6 | 1 |
| Cash Flow from Ops. ⓘ | -0.1 | 0.3 | -0.1 | 3.4 | 0.2 | 0.3 | -0.5 | 2.4 | 0.8 | 2.6 | - |
| Debt/CF from Ops. ⓘ | -13.5 | 6.3 | -14.8 | 1 | 28.3 | 15.1 | -11.3 | 1.9 | 6.2 | 1.6 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 5.5% | 10.5% | 13.2% | -20.9% | ||||
| Adj EPS ⓘ | 22.8% | 66.2% | NA | -24% | ||||
| BVPSⓘ | 4% | 4.5% | 9.3% | 6.6% | ||||
| Share Price | 3% | 11.1% | 3.7% | 3.8% | ||||
Key Financial Parameters ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 1.4 | 1.6 | 10 | 8.4 | 0.6 | -1 | -8.6 | 10 | 9 | 6.3 | 6.4 |
| Op. Profit Mgn % ⓘ | 3.8 | 4.5 | 6.9 | 8 | 7.1 | 10.3 | 3 | 7.4 | 8.2 | 4.7 | 11.8 |
| Net Profit Mgn % ⓘ | 0.7 | 1 | 4.4 | 4.6 | 0.4 | -0.5 | -4.5 | 2.9 | 2.9 | 2.7 | 2.9 |
| Debt to Equity ⓘ | 0.3 | 0.3 | 0.2 | 0.4 | 0.7 | 0.7 | 0.7 | 0.6 | 0.6 | 0.4 | - |
| Working Cap Days ⓘ | 170 | 215 | 185 | 195 | 186 | 232 | 266 | 146 | 151 | 176 | 66 |
| Cash Conv. Cycle ⓘ | 104 | 149 | 114 | 95 | 72 | 93 | 114 | 58 | 76 | 112 | 21 |
Valuation of Beryl Drugs - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
No data found!
No data found!
No data found!
No data found!
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Beryl Drugs Ltd FAQs
The current trading price of Beryl Drugs on 25-Sep-2026 16:59 is ₹23.23.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 24-Sep-2026 the market cap of Beryl Drugs stood at ₹11.78 Cr
The latest P/E ratio of Beryl Drugs as of 24-Sep-2026 is 18.88.
The latest P/B ratio of Beryl Drugs as of 24-Sep-2026 is 1.17.
The 52-week high of Beryl Drugs is ₹27.60 and the 52-week low is ₹15.92.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Beryl Drugs is ₹21.32 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Beryl Drugs Ltd is a below average quality company.
The key valuation ratios of Beryl Drugs Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Beryl Drugs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Beryl Drugs Ltd
Beryl Drugs incorporated in 1993 is into manufacturing and marketing of branded, generic pharmaceutical formulations. The company is one of leading manufacturer of I.V.fluids and small volume injectables.
Beryl has emerged into a global network of pharmaceutical manufacturing, research and development, contract manufacturing services and veterinary products.
The manufacturing facilities of the company are in compliance with WHO GMP specifications.
Company owns brands like BERI-CEF injection, F-Neuron, Amplicillin INJ, P-Mol, Biprox, B-Flox and many more.
The shares of Beryl Drugs are listed on M.P. Stock Exchange, Bombay Stock Exchange and Ahmedabad Stock Exchange.
Products manufactured by the company:
- Small volume injectables in liquid form
- Small volume injectables in dry powder form
- Variety of eye and ear drops
- I.V.Fluids in polypack and glass bottles
- Variety of vetrinary medicines
Award/recognition
The company has received ISO 9001:2000 certification for its quality management.
You have 40 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
